Literature DB >> 35373108

Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: PRO.

Subodh R Devabhaktuni1, J Paul Mounsey1.   

Abstract

Entities:  

Keywords:  ESKD; ESRD; OAC; apixaban; clinical nephrology; coumadin

Mesh：

Substances：

Year:  2021        PMID： 35373108      PMCID： PMC8786127          DOI： 10.34067/KID.0000022021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  19 in total

1.  Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.

Authors:  Konstantinos C Siontis; Xiaosong Zhang; Ashley Eckard; Nicole Bhave; Douglas E Schaubel; Kevin He; Anca Tilea; Austin G Stack; Rajesh Balkrishnan; Xiaoxi Yao; Peter A Noseworthy; Nilay D Shah; Rajiv Saran; Brahmajee K Nallamothu
Journal:  Circulation       Date:  2018-10-09       Impact factor: 29.690

2.  Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease.

Authors:  Felix Yang; Jessica A Hellyer; Claire Than; Aditya J Ullal; Daniel W Kaiser; Paul A Heidenreich; Donald D Hoang; Wolfgang C Winkelmayer; Susan Schmitt; Susan M Frayne; Ciaran S Phibbs; Mintu P Turakhia
Journal:  Heart       Date:  2016-11-15       Impact factor: 5.994

3.  Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis.

Authors:  Ronpichai Chokesuwattanaskul; Charat Thongprayoon; Tanyanan Tanawuttiwat; Wisit Kaewput; Pavida Pachariyanon; Wisit Cheungpasitporn
Journal:  Pacing Clin Electrophysiol       Date:  2018-04-23       Impact factor: 1.976

4.  Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.

Authors:  Ming Chang; Zhigang Yu; Andrew Shenker; Jessie Wang; Janice Pursley; Wonkyung Byon; Rebecca A Boyd; Frank LaCreta; Charles E Frost
Journal:  J Clin Pharmacol       Date:  2015-12-04       Impact factor: 3.126

5.  Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.

Authors:  Anders Nissen Bonde; Gregory Y H Lip; Anne-Lise Kamper; Peter Riis Hansen; Morten Lamberts; Kristine Hommel; Morten Lock Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Jonas Bjerring Olesen
Journal:  J Am Coll Cardiol       Date:  2014-12-16       Impact factor: 24.094

6.  Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.

Authors:  Kevin E Chan; J Michael Lazarus; Ravi Thadhani; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

7.  Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.

Authors:  Xiaoli Wang; Giridhar Tirucherai; Thomas C Marbury; Jessie Wang; Ming Chang; Donglu Zhang; Yan Song; Janice Pursley; Rebecca A Boyd; Charles Frost
Journal:  J Clin Pharmacol       Date:  2015-12-22       Impact factor: 3.126

8.  Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease.

Authors:  Sean D Pokorney; Eric Black-Maier; Anne S Hellkamp; Daniel J Friedman; Sreekanth Vemulapalli; Christopher B Granger; Laine Thomas; Eric D Peterson; Jonathan P Piccini
Journal:  J Am Coll Cardiol       Date:  2020-03-24       Impact factor: 24.094

9.  Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin.

Authors:  Hoang M Lai; Wilbert S Aronow; Phoenix Kalen; Sreedhar Adapa; Kaushal Patel; Arvind Goel; Ravi Vinnakota; Savneek Chugh; Renee Garrick
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-11-19

10.  Evaluation of hemostasis in patients with end-stage renal disease.

Authors:  Anja Gäckler; Hana Rohn; Ton Lisman; Tamas Benkö; Oliver Witzke; Andreas Kribben; Fuat H Saner
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.